P18.02 Factors Influencing Multi-Disciplinary Tumor Board Recommendations in Stage III Non-Small Cell Lung Cancer
نویسندگان
چکیده
منابع مشابه
Treatment of Stage III Non-small Cell Lung Cancer
Treatment of Stage III Non-small Cell Lung Cancer Objectives: Stage III non-small cell lung cancer (NSCLC) describes a heterogeneous population with disease presentation ranging from apparently resectable tumors with occult microscopic nodal metastases to unresectable, bulky nodal disease. This review updates the published clinical trials since the last American College of Chest Physicians guid...
متن کاملNeoadjuvant Chemoradiotherapy for Stage III Non-Small Cell Lung Cancer
The local management of stage III non-small cell lung cancer is controversial. Although definitive chemoradiotherapy (CRT) is considered a standard-of-care in the curative management of the disease, inadequate local control outcomes have led to various treatment strategies that incorporate surgical resection. Surgery alone has long been recognized as insufficient for this stage, and thus neoadj...
متن کاملPrognostic Factors in Stage III Non-Small-Cell Lung Cancer Patients
Aim: The objective of this study is to investigate prognostic factors affecting survival of patients undergoing concurrent or sequential chemoradiotherapy (CRT) for stage III non-small-cell lung cancer (NSCL). Methods and materials: We retrospectively reviewed the clinical records of 148 patients with advanced, inoperable stage III NSCLC, who were treated between 2007 and 2015. Results: The med...
متن کاملLocoregional tumor failure after definitive radiation for patients with stage III non-small cell lung cancer
BACKGROUND Locoregional tumor failure (LRF) after definitive chemoradiation for patients with stage III NSCLC remains unacceptably high. This analysis sought to further define where LRF occurs relative to radiation dose received and pre-treatment PET scan-defined maximum standard uptake value (SUVmax). METHODS This was a retrospective study analyzing patients with stage III NSCLC treated with...
متن کامل2nd ESMO Consensus Conference in Lung Cancer: locally advanced stage III non-small-cell lung cancer.
To complement the existing treatment guidelines for all tumour types, ESMO organises consensus conferences to focus on specific issues in each type of tumour. The 2nd ESMO Consensus Conference on Lung Cancer was held on 11-12 May 2013 in Lugano. A total of 35 experts met to address several questions on non-small-cell lung cancer (NSCLC) in each of four areas: pathology and molecular biomarkers,...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Journal of Thoracic Oncology
سال: 2021
ISSN: ['1556-0864', '1556-1380']
DOI: https://doi.org/10.1016/j.jtho.2021.01.558